UW228-3 Xenograft Model Service for Medulloblastoma

The UW228-3 xenograft model represents a well-characterized preclinical platform for medulloblastoma research, enabling robust evaluation of therapeutic agents targeting SHH-activated, TP53-mutant pediatric brain tumors. Alfa Cytology delivers comprehensive UW228-3 xenograft model services tailored to your drug discovery pipeline, combining rigorous quality control with customizable study designs to accelerate your preclinical development programs.

Overview of UW228-3 Xenograft Model for Medulloblastoma

The UW228-3 cell line was established from a posterior fossa medulloblastoma specimen and represents one of the most extensively characterized SHH-activated, TP53-mutant medulloblastoma models available for preclinical research. This cell line exhibits aneuploid karyotype with modal chromosome numbers similar to its parental tumor, displays loss of heterozygosity at the distal end of chromosome 17p, and maintains expression of neuronal differentiation markers including neurofilament proteins and synaptophysin. UW228-3 cells demonstrate anchorage-independent growth in soft agar, form tumorspheres under appropriate culture conditions, and express cancer stem cell markers CD15 and ALDH, making this model particularly valuable for studying tumor initiation, therapy resistance, and stem cell biology in medulloblastoma.

In xenograft applications, UW228-3 tumors reliably recapitulate key histopathological features of human medulloblastoma, including small round blue cell morphology, high proliferative indices, and regions of necrosis. The model has been instrumental in elucidating the role of c-MYC dysregulation in driving anaplastic transformation, evaluating DNA repair mechanisms following radiation exposure, and testing novel therapeutic strategies including SMO inhibitors, glutamine metabolism inhibitors, and alkylating agents. When cultured under neural stem cell conditions prior to orthotopic implantation, UW228-3 cells demonstrate enhanced homing capacity to the cerebellar region and improved tumor take rates, providing a more physiologically relevant platform for therapeutic evaluation.

• Efficacy Testing: Evaluating the in vivo anti-tumor activity of novel compounds, small molecules, biologics, or combination therapies targeting SHH-activated, TP53-mutant medulloblastoma.
• Mechanistic Studies: Investigating the complex molecular pathways driving medulloblastoma progression and c-MYC-driven anaplastic transformation, and how treatments intersect with these pathways.
• Biomarker Discovery: Identifying and validating potential biomarkers for treatment response or resistance in a controlled in vivo environment, particularly for cancer stem cell markers and DNA repair capacity.

Figure 1. WST-1 viability assays after single treatment of FGFR and PI3K inhibitors on five MB cell lines. (Holzhauser, Stefan, et al., 2020)

Cell Line Information: UW228-3

The UW228-3 cell line is a well-established human medulloblastoma line with comprehensive molecular characterization. Its SHH-activated, TP53-mutant molecular profile and cancer stem cell properties make it unique among available medulloblastoma cell lines and essential for preclinical research targeting this aggressive pediatric brain tumor subtype.

Our Services

Alfa Cytology provides end-to-end UW228-3 xenograft model services designed to streamline your preclinical drug development workflow. Our experienced team manages every phase from cell line authentication and quality control through tumor monitoring, endpoint analysis, and comprehensive data reporting, ensuring reproducible results that meet the highest standards of scientific rigor. Whether you require standard subcutaneous implantation, orthotopic cerebellar injection, or customized study protocols with molecular imaging and biomarker analysis, Alfa Cytology delivers reliable, publication-ready data to advance your therapeutic candidates.

Workflow of UW228-3 Xenograft Model Construction

The construction of UW228-3 xenograft models follows a standardized yet adaptable workflow that ensures tumor reproducibility, animal welfare compliance, and data integrity. At Alfa Cytology, we adhere to an optimized, multi-step workflow to ensure maximum take rates and reproducible growth kinetics. The streamlined workflow involves:

1. Cell Line Authentication and Preparation: UW228-3 cells are authenticated via STR profiling and confirmed free of mycoplasma contamination. Low-passage cells are expanded under standard culture conditions or adapted to neural stem cell media for orthotopic studies, then harvested at optimal confluence for implantation.
2. Animal Selection and Acclimation: Immunodeficient mice (typically nu/nu or NOD-scid) are selected based on study requirements and acclimated for 7-14 days. Health status is verified, and animals are randomized into treatment groups using stratified body weight allocation.
3. Tumor Cell Implantation: For subcutaneous models, UW228-3 cells (typically 1-5 x 10^6 cells in 100-200 uL Matrigel/PBS mixture) are implanted into the flank. For orthotopic cerebellar models, cells are stereotactically injected into the posterior fossa using precision coordinates to target the cerebellar hemisphere.
4. Tumor Monitoring and Growth Assessment: Tumor dimensions are measured via caliper twice weekly for subcutaneous models, or through bioluminescence imaging (BLI) and MRI for orthotopic models. Body weight and clinical signs are monitored daily to ensure animal welfare compliance.
5. Treatment Administration: Test compounds are administered according to predefined dosing regimens (route, frequency, and duration). Treatment initiation typically occurs when tumors reach 100-200 mm^3 (subcutaneous) or at specified BLI signal thresholds (orthotopic).
6. Endpoint Analysis and Sample Collection: At study termination, tumors are excised, weighed, and photographed. Tissues are processed for histopathology (H&E, IHC), molecular analysis (RNA/DNA/protein extraction), and pharmacokinetic studies. Blood samples are collected for hematology and clinical chemistry.
7. Data Analysis and Reporting: Tumor growth inhibition (TGI), survival curves, and biomarker data are analyzed using appropriate statistical methods. A comprehensive study report including methodology, raw data, and interpretive summary is delivered to the sponsor.

Figure 2: Schematic workflow illustrating the derivation and construction of the UW228-3 Xenograft Model at Alfa Cytology.

Case Study-UW228-3 Xenograft Model Development

Alfa Cytology has successfully developed and validated UW228-3 xenograft models across multiple study formats, including subcutaneous flank implants and orthotopic cerebellar injections in immunodeficient mouse strains. Our internal validation studies demonstrate consistent tumor take rates, reproducible growth kinetics, and appropriate histopathological features consistent with SHH-activated medulloblastoma. Detailed tumor growth curves, survival data, pharmacokinetic profiles, and biomarker analysis results are available upon request. Please contact our scientific team to discuss specific study parameters, historical control data, and customized model development options for your therapeutic program.

Why Choose Alfa Cytology?

Alfa Cytology combines scientific expertise with operational excellence to deliver UW228-3 xenograft model services that meet the demanding requirements of modern drug development programs. Our integrated approach ensures seamless study execution from conception to completion, providing you with reliable data and strategic insights to advance your therapeutic candidates efficiently.

• Verified Cell Line Integrity: Extensive experience with pediatric brain tumor models including SHH, WNT, Group 3, and Group 4 medulloblastoma subtypes.
• High Take Rates and Consistency: Rigorous cell line authentication and quality control protocols ensure model integrity and reproducibility across studies.
• Comprehensive Analytical Support: Flexible study designs accommodating subcutaneous, orthotopic, and patient-derived xenograft formats with molecular imaging capabilities.
• Tailored Study Designs: Comprehensive endpoint analysis including histopathology, immunohistochemistry, biomarker profiling, and pharmacokinetic evaluation.
• Standardized Protocols: Dedicated project management with transparent communication, real-time data access, and timely delivery of comprehensive study reports.
• Dedicated Project Management: Competitive pricing structures and milestone-based payment options tailored to biotech and pharmaceutical client needs.
• Regulatory Compliance: Full compliance with IACUC guidelines, AAALAC standards, and international animal welfare regulations.

Contact Us

Ready to advance your medulloblastoma therapeutic program with a validated UW228-3 xenograft model? Contact us today to discuss your specific research requirements, receive a detailed proposal, and learn how Alfa Cytology can accelerate your preclinical development timeline. Our scientific team is available to reach out and provide expert guidance on study design, model selection, and regulatory considerations. Please reach out to us today via our inquiry form or email to learn more about our UW228-3 Xenograft Model services.

For research use only. Not intended for any clinical use.